Kwang-Soo Kim Ph.D. is a Professor at Harvard Medical School and Director of the Molecular Neurobiology Laboratory at McLean Hospital, and also the Masson Family Endowed Scholar at Massachusetts General Hospital. He has over 30 years of experience investigating the molecular neurobiology of midbrain dopamine neuronal systems in health and disease, focusing on elucidating the genetic network of intrinsic signaling molecules and the extrinsic transcription factors underlying the development and maintenance of dopamine neurons. These investigations led to the identification of the orphan nuclear receptor Nurr1 as a promising molecular target to treat Parkinson’s disease (PD). To further the development of novel mechanism-based disease-modifying drugs, based on recent findings, Dr. Kim established NurrON pharma (https://nurronpharma.com/) for clinical applications. In addition, Dr. Kim focuses on furthering our understanding of somatic cell reprogramming and differentiation, allowing him to establish a platform of key technologies propelling the development of personalized cell therapy for PD using patients’ own cells. Based on these progresses, he obtained FDA approval, leading to successful treatment of the first PD patient in 2017 (Schweitzer et al., 2020, NEJM), which has recently been selected as one of 25 major discoveries in stem cell research by the International Society of Stem Cell Research (ISSCR) in 2022 (Lendahl, 100 plus years of stem cell research-20 years of ISSCR, Stem Cell Reports, 2022, 17:1248).